For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available.
Scope of the Report:
This report focuses on the Human Prothrombin Complex in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The global average price of Human Prothrombin Complex is in the increasing trend, from 124 USD/Unit in 2013 to 137 USD/Unit in 2017. With the situation of global economy, prices will be in increasing trend in the following five years.
The classification of Human Prothrombin Complex includes 500 IU/Vial, 600 IU/Vial, 1000 IU/Vial and others, and the proportion of 500 IU/Vial in 2017 is about 51%.
Human Prothrombin Complex is widely used in Hemophilia B, Vitamin K Deficiency and other diseases. The most proportion of Human Prothrombin Complex is Hemophilia B, and the proportion of sales is 48%.
North America is the largest consumption place, with a consumption market share nearly 46% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 33%.
Market competition is not intense. Shire, CSL, Grifols, Octapharma, Hualan Biological, Meheco Xinxing Pharma, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The worldwide market for Human Prothrombin Complex is expected to grow at a CAGR of roughly 11.8% over the next five years, will reach 1940 million US$ in 2023, from 1000 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Hualan Biological
- Meheco Xinxing Pharma
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- 500 IU/Vial
- 600 IU/Vial
- 1000 IU/Vial
Market Segment by Applications, can be divided into
- Hemophilia B
- Vitamin K Deficiency
There are 15 Chapters to deeply display the global Human Prothrombin Complex market.
Chapter 1, to describe Human Prothrombin Complex Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Human Prothrombin Complex, with sales, revenue, and price of Human Prothrombin Complex, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Human Prothrombin Complex, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Human Prothrombin Complex market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Human Prothrombin Complex sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source